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Abstract
Background: This study was designed to determine the pattern and correlation between expression of the HIF-1a
transcriptional targets TGM2 and BNIP3 in laryngeal cancer, and investigate the association of BNIP3 and TGM2
with clinical outcome in laryngeal squamous cell carcinoma (SCC) patients receiving postoperative radiotherapy.
Methods: Immunostaining with antibodies specific to BNIP3 and TGM2 was performed in formalin-fixed, paraffin-
embedded specimens from 148 laryngeal SCC patients. BNIP3 and TGM2 expression was scored as high or low,
based on the number of tumor cells stained and the staining intensity. All patients received postoperative
radiotherapy. Patient follow up and clinicopathological data were compared using the Chi-squared test, univariate
and multivariate analyses, and survival curves were generated using the Kaplan-Meier method and log-rank test.
Results: The 3, 5 and 10-year overall survival rates (OS) for all patients were 77.7%, 71.6%, 56.4%, respectively.
Primary tumor site, T stage, overall stage, lymph-node metastasis, BNIP3 expression and TGM2 expression were
significant prognostic factors for OS in univariate analysis. Negative cervical lymph nodes, high BNIP3 expression
and low TGM2 expression were independent prognostic factors of improved OS in multivariate analysis. BNIP3
expression correlates with TGM2 expression in laryngeal SCC (P = 0.012).
Conclusions: This study indicates that lymph-node metastasis, BNIP3 expression and TGM2 expression are
independent prognostic factors in laryngeal SCC patients receiving postoperative radiotherapy. Further studies are
required to investigate how BNIP3 and/or TGM2 influence the prognosis of laryngeal SCC patients treated with
postoperative radiotherapy, and to determine how TGM2 and BNIP3 expression are regulated.
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Background
In the United States, laryngeal cancer accounted for
approximately 0.85% of new cancer diagnoses and 0.65%
of all cancer deaths in 2008 [1]. Postoperative radiother-
apy (PRT) is widely advocated for squamous cell carci-
noma (SCC) of the head and neck patients with a high
risk of recurrence after surgical resection.
The most important factor in the prognostic evalua-
tion of head and neck squamous cell carcinoma
(HNSCC) is the tumor node metastasis (TNM) staging
system, of which nodal stage is the most relevant factor.
However, the outcome of patients with the same TNM
stage can vary, which has led to a concerted effort to
define additional TNM subcategories with a similar
prognosis, and recent research has focused on the iden-
tification of molecular and biologic prognostic factors,
regardless of TNM staging.
The hypoxic fraction of human cancers is resistant to
radiation therapy due to reduced generation of oxygen
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any medium, provided the original work is properly cited.radicals. The transcription factor hypoxia-inducible fac-
tor-1 (HIF-1a) upregulates expression of a variety of tar-
get genes under hypoxic conditions, and plays a major
role in determining tumor radiosensitivity. Therefore,
HIF-1a and HIF-1a target genes represent potential
therapeutic targets to influence the effect of hypoxia on
tumor radiosensitivity.
BNIP3, a hypoxia-inducible pro-apoptotic gene
belonging to the BCL2 family, was originally identified
as an adenovirus E1B19-kDa protein-interacting gene. In
normal tissues, BNIP3 expression is upregulated in
hypoxic conditions by hypoxia inducible factor HIF-1a
and can lead to cell death [2-4]. In tumors, BNIP3 is
silenced via epigenetic mechanisms, such as promoter
hypermethylation and histone deacetylation [5]. Down-
regulation of BNIP3 results in the failure of tumor cells
to undergo cell death, and is associated with chemore-
sistance and poorer survival [6,7].
The transglutaminase 2 (TGM2) family catalyze for-
mation of an amide bond between the carboxamide
groups of peptide-bound glutamine residues and pri-
mary amino groups in various compounds [8]. One
member of the TGM2 family, TGase 2 (TGM2) can
enhance the survival of hypoxic cells and has been iden-
tified as a HIF-1a transcriptional target. Hypoxia upre-
gulates TGM2 expression via a HIF-1a dependent
pathway and concurrently activates intracellular TGM2
activity [9]. Increased expression of TGM2 is associated
with drug resistance in cancer [10], due to activation of
nuclear factor-kB (NF-kB) via cross-linking and poly-
merization of free I-kB by TGM2 [11].
Although BNIP3 and TGM2 are associated with drug
resistance and provide valuable prognostic markers in a
variety of cancers [6,7,10], the expression and signifi-
cance of BNIP3 and TGM2 have not been investigated
in patients with laryngeal SCC receiving postoperative
radiotherapy. Therefore, we examined the pattern and
correlation between TGM2 and BNIP3 expression to
determine their association with clinical factors and out-
come in patients with SCC of the larynx.
The results of this study indicate that, in addition to
lymph node involvement, the expression levels of BNIP3
and TGM2 are novel independent predictive factors for
survival in laryngeal SCC patients receiving postopera-
tive radiotherapy.
Methods
Patients and tissue samples
This study was approved by the Institutional Review
Board and Human Ethics Committee of Sun Yet-sen
University Cancer Center. A total of 148 patients with
histologically confirmed SCC of the larynx treated from
1997 to 2003 at the Sun Yet-sen University Cancer Cen-
ter were included. Relevant clinical pathologic features
(Table 1) were obtained from the medical files and/or
by telephone interviews with the patient or their rela-
tives. Tumor types and histological grade classifications
were designated according to World Health Organiza-
tion classification of Tumors: Pathology and Genetics of
Head and Neck Tumors [12].
Table 1 Expression of TGM2 and BNIP3 and their
relationship with clinicopathological characteristics in
laryngeal squamous cell carcinoma patients
Features No. of
patients
TGM2 P BNIP3 P
High Low High Low
Gender
Female 3(2.0%) 0 3 0.283
a 1 2 0.194
b
Male 145(98.0%) 70 75 105 40
Age (years)
c
< 60 72(48.6%) 35 37 0.755 52 20 0.875
≥60 76(51.4%) 35 41 54 22
Histological grade
Well 70(47.3%) 37 33 0.184 50 20 0.933
Moderately 58(39.2%) 22 36 41 17
Poorly 20(13.5%) 11 9 15 5
Smoking index
d
< 600 67(45.3%) 36 31 0.154 52 15 0.651
≥600 81(54.7%) 34 47 54 27
Alcohol consumption
No 88(59.5%) 40 48 0.587 56 32 0.009**
Yes 60(40.5%) 30 30 50 10
Primary Site
Glottic 104(70.3%) 50 54 0.433 74 30 0.791
Supraglottic 39(26.3%) 19 20 29 10
Subglottic 5(3.4%) 1 4 3 2
T Stage
1-2 101(68.2%) 47 54 0.785 71 30 0.600
3-4 47(31.8%) 23 24 35 12
Cervical lymph node metastasis
Positive 19(12.8%) 9 10 0.995 17 2 0.064
Negative 129(87.2%) 61 68 89 40
TNM Stage
I-II 96(64.9%) 46 50 0.838 67 29 0.502
III-IV 52(35.1%) 24 28 39 13
Total radiation dose
< 60 Gy 61(41.2%) 24 37 0.105 41 20 0.319
≥60 Gy 87(58.8%) 46 41 65 22
Margin
Negative 68(45.9%) 38 30 0.054 50 18 0.635
Positive 80(54.1%) 32 48 56 24
BNIP3
High 106(71.6%) 57 49 0.012*
Low 42(28.4%) 13 29
a Continuity correction.
bFisher’s exact test.
c Patients were divided according
to the median age.
d Smoking index is defined as the number of cigarettes
used per day × the total smoking time (years). *P < 0.05, **P < 0.01
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All patients underwent a major surgical intervention at
Sun Yet-sen University Cancer Center; patients irra-
diated after excisional biopsies were not included in the
study. In total, 116/148 (78.4%) of the laryngeal SCC
patients were treated with partial laryngectomy and 32/
148 (21.6%) were treated with total laryngectomy. Uni-
lateral or bilateral neck node dissection was performed
in 79 (53.4%) of the patients.
Radiotherapy
The indications for postoperative radiotherapy in our
hospital at the time of the study included clinically or
microscopically positive surgical margins, pathologically
confirmed positive neck nodes and/or the advanced clin-
ical stages of primary laryngeal cancer (T3, T4). Only
patients in good general condition with no distant
metastases were considered for PRT.
The total radiation dose in the clinical target volume
area ranged from 36 to 82 Gy, with a median value of
60 Gy. Lower doses (< 50 Gy) were given to patients
whose clinical condition demanded premature termina-
tion of the treatment (due to local progression during
PRT, deteriorating performance status or intercurrent
disease) or patients who refused to complete treatment.
Higher doses (> 70 Gy) were given to patients with a
clinically palpable mass after surgery, or patients who
required an increased total dose due to long duration
treatment gaps.
Immunohistochemistry (IHC) staining
A total of 148, routinely processed laryngeal squamous
cell carcinoma paraffin-embedded samples were cut into
4 μm sections, dried overnight at 56°C, deparaffinized,
rehydrated, antigen retrieval was performed in citrate
buffer at 92°C using a microwave oven and the sections
were incubated in 3% H2O2 to block endogenous perox-
idase activity. The sections were incubated in mouse
monoclonal [CUB 7402] anti-TGM2 antibody (ab2386,
ABCAM, dilution 1:100) or mouse monoclonal [Ana40]
anti-BNIP3 antibody (ab10433, ABCAM, dilution 1:100)
overnight at 4°C in a humidified chamber, staining was
visualized using an avidin-biotin technique and DAB
staining, followed by hematoxylin nuclear counterstain-
ing. Negative controls were prepared by omitting the
primary antibody. Histological and IHC evaluation were
performed independently by two pathologists while
blinded to the clinicopathological outcomes of the
patients. Slides with indeterminate evaluation were re-
evaluated, and a consensus was reached. Briefly, each
slide was examined in its entirety under a light micro-
scope. Pilot studies indicated BNIP3 staining was both
nuclear and cytoplasmic (Figure 1); therefore, the inten-
sity of nuclear and cytoplasmic staining was defined as
no staining (0), weak staining (1), moderate staining (2)
or strong staining (3), and the percentage of cells
stained was scored as 0-10% (1), 10-50% (2), 51-80% (3)
or 81-100% (4). Tumors were considered highly positive
if they demonstrated moderate or strong staining (2 or
3) in greater than 50% of cells (3 or 4). TGM2 expres-
sion was scored using the same intensity, percentage
scores and positive criteriaa sB N I P 3 ,a sp r e v i o u s l y
reported [13].
Statistical methods
Statistical analysis was performed using SPSS 13.0 for
Windows. The c
2 test was used to evaluate categorical
variables. Associations between clinicopathological fea-
tures and TGM2 or BNIP3 immunohistochemical
expression were analyzed using the Pearson chi-square
test of independence. Multivariate survival analyses were
performed using the Cox regression model. Overall sur-
vival (OS) was measured from the onset of treatment to
the date of death or survival status at the last date of
follow-up. OS probabilities were estimated using the
Kaplan- Meier method and significant differences were
assessed using the log-rank test. P values < 0.05 were
considered statistically significant, and P values < 0.01
were considered strongly statistically significant.
Results
Clinicopathological features
In total, 148 laryngeal SCC patients (145 males and 3
females) with a median age of 60 years (range: 23-85
years) were included in this study. Table 1 presents a
summary of the gender, age,t u m o rs i t e ,t u m o rs t a g e ,
histological grade, smoking index, alcohol consumption,
total radiation dose and surgery margins of the patients.
According to the 6th Edition of the International Union
Against Cancer (UICC) TNM classification system, 26
patients were Stage I, 70 were Stage II, 28 were Stage III
and 24 were Stage IV.
Patient outcomes after follow-up
The last follow-up date was June 29th, 2010, and no
patients were lost during follow-up. The 3, 5 and 10
year overall survival rates (OS) for all patients were
77.7%, 71.6% and 56.4%, respectively (Figure 2). Sixty
two cancer-related deaths were reported, with a median
time to death of 35 months (range 1-108 months).
There are 6 non-cancer-related deaths. The median
time to non-cancer-related death is 30 months (range
18-78 months).
Immunohistochemical expression of TGM2 and BNIP3
Positive expression of BNIP3 was mainly localized in the
nucleus, with some expression detected in the cytoplasm
of laryngeal SCC tumor cells. Positive expression of
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geal SCC tumor cells, with some expression detected in
the nucleus (Figure 1). The immunostaining scores are
listed in the Table 1. TGM2 was highly positive in
47.3% (70/148) of the tumors, and BNIP3 was highly
positive in 71.6% (106/148) of the tumors. Furthermore,
highly positive BNIP3 expression was correlated with
highly positive TGM2 expression (P =0 . 0 1 2 )a n da l c o -
hol consumption (P = 0.009; Table 1).
BNIP and TGM2 are associated with patient prognosis
Univariate analyses indicated a significant association
between OS and primary tumor site, T stage, cervical
lymph node metastasis, TNM stage, TGM2 expression
and BNIP3 expression in laryngeal SCC (Table 2, Figure
2). Patients with both high BNIP3 expression and low
TGM2 expression had a significantly better overall survi-
val, compared to patients with low BNIP3 expression and
high TGM2 expression, respectively (P <0 . 0 0 1 ) .T h e3 ,5
and 10-year overall survival rates (OS) of patients who
expressed high levels of BNIP3 and low levels of TGM2
were 87.8%, 85.7% and 76.9%, respectively.
Multivariate analysis
Multivariate survival analysis was performed using the
Cox regression model to calculate the odds ratio and
95% confidence intervals for each clinicopathological
variable. The model was simplified in a stepwise fashion
by removing variables with a P value ≥0.05. The analysis
revealed that TGM2 expression status, BNIP3 expres-
sion status and cervical lymph node metastasis were sta-
tistically significant independent predictive factors for
OS in laryngeal SCC patients (Table 3).
Discussion
In this study we evaluated the significance of various
prognostic factors in patients with SCC of the larynx
treated with primary surgery and PRT. No patients
received any other form of adjuvant systemic treatment.
The overall survival (OS) of the patients was
 
Figure 1 Immunohistochemical staining for TGM2 and BNIP3 in laryngeal squamous cell carcinoma. Positive expression of BNIP3 was
mainly localized in the nucleus, but was also observed in the cytoplasm of tumor cells. Positive expression of TGM2 was mainly localized in the
cytoplasm of tumor cells, but was also observed in the nucleus. Representative images of (A) highly positive BNIP3 expression in tumor cells, (B)
low BNIP3 expression in tumor cells, (C) highly positive TGM2 expression in tumor cells and (D) low TGM2 expression in tumor cells (SP × 400)
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Page 4 of 9significantly related to the UICC stage, in agreement
with previous reports that the initial classification (T
stage, N stage and total stage) are significant prognostic
factors for survival in laryngeal SCC [14-17]. In this
study, univariate analysis also indicated that tumor sites
in the supraglottis were correlated with a significantly
poorer prognosis.
It has been reported that the number, site and volume
of metastatic lymph nodes can negatively influence the
prognosis in laryngeal carcinoma [18,19], and these
results were confirmed by our study, as univariate analy-
sis indicated that the presence of metastatic lymph
nodes (P <0 . 0 0 1 )h a dan e g a t i v ep r o g n o s t i cv a l u e .T h e
relationship between nodal involvement and local
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Figure 2 Survival curves for laryngeal squamous cell carcinoma patients. (A) Overall survival (OS) for all patients. (B) OS in patients with
different primary tumor sites. (C) OS in patients with different T stages. (D) OS in patients with and without cervical lymph node metastasis. (E)
OS in patients with different UICC stages. (F) OS in patients with high and low TGM2 expression. (G) OS in patients with high and low BNIP3
expression. (H) OS in patients with high and low BNIP3 and TGM2 expression.
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Page 5 of 9control has been examined in several patient series. van
den Bogaert et al. and Wall et al. [20,21] reported 5 year
local control rates of 70% and 79% in patients without
positive node involvement, compared to 49% and 57%
in patients with clinically positive nodes. Three large
multicenter studies of laryngeal SCC patients treated
with PRT have reported similar recurrence rates [22-24],
indicating that cervical lymph node status is the most
important tumor-related prognostic factor in head and
neck cancer patients. Additionally, the incidence of local
recurrence and risk of distant metastases increase as the
tumor burden in the neck increases [25,16].
To our knowledge, no previous studies have evaluated
the prognostic value of TGM2 and BNIP3 in head-and-
neck cancer in patients treated with PRT. In this study,
univariate analyses and multivariate analysis indicated
that high expression of TGM2 and/or low expression of
BNIP3 are associated with poorer overall survival in lar-
yngeal SCC patients receiving PRT.
Several factors may explain the association between
high expression of TGM2 and poorer OS. TGM2
expression can promote cell surface interaction with
fibronectin and protect breast cancer cells from apopto-
sis [26]. Intense expression at the stromal-epithelial
i n t e r f a c es u g g e s t st h a tT G M 2p l a y sar o l ei nc e l la d h e -
sion, cell migration, invasiveness and metastasis [27],
and Dardik et al. reported that stromal expression of
TGM2 in the endothelium of newly formed blood ves-
sels may lead to tumor growth and metastasis [28].
Table 2 The relationship of clinicopathological variables
and immunohistochemical features with overall survival
(OS) in laryngeal squamous cell carcinoma patients
Feature No. of
patients
Overall
survival (%)
c
2 P
a
3y 5y 1 0
y
Gender 1.539 0.215
Female 3(2.0%) 100 100 100
Male 145(98.0%) 77.2 71.0 55.6
Age (years)
b 0.019 0.889
< 60 72(48.6%) 80.6 72.2 54.9
≥60 76(51.4%) 75 71.1 57.6
Histological grade 2.976 0.226
Well 70(47.3%) 85.7 81.4 60.8
Moderately 58(39.2%) 69.0 62.1 51.2
Poorly 20(13.5%) 75.0 65.0 55.0
Smoking index
c 3.745 0.053
< 600 67(45.3%) 83.6 77.6 66.2
≥600 81(54.7%) 72.8 66.7 48.4
Alcohol consumption 0.033 0.856
No 88(59.5%) 79.5 71.6 56.8
Yes 60(40.5%) 75.0 71.7 55.6
Primary Site 8.974 0.011*
Glottic 104(70.3%) 82.7 77.9 63.1
Supraglottic 39(26.3%) 64.1 53.8 39.0
Subglottic 5(3.4%) 80.0 80.0 40.0
T Stage 6.201 0.013*
1-2 101(68.2%) 81.2 78.2 62.6
3-4 47(31.8%) 70.2 57.4 43.5
Cervical lymph node metastasis 21.263 <
0.001**
Negative 129(87.2%) 82.9 77.5 61.7
Positive 19(12.8%) 42.1 31.6 21.1
TNM Stage 7.736 0.005**
I-II 96(64.9%) 82.3 79.6 63.8
III-IV 52(35.1%) 69.2 57.7 43.3
Total radiation dose 1.671 0.196
< 60 Gy 61(41.2%) 78.7 75.4 62.9
≥60 Gy 87(58.8%) 77.0 69.0 51.7
Margin 0.395 0.530
Negative 68(45.9%) 82.4 76.5 57.9
Positive 80(54.1%) 73.8 67.5 55.0
TGM2 6.308 0.012*
High 70(47.3%) 72.9 64.3 45.5
Low 78(52.7%) 82.1 78.2 65.7
BNIP3 8.586 0.003**
High 106(71.6%) 79.2 75.5 64.4
Low 42(28.4%) 71.4 61.9 35.7
TGM2 & BNIP3 19.021 <
0.001**
TGM2 (-) & BNIP3
(+)
49(33.1%) 87.8 85.7 76.9
TGM2 (+) & BNIP3
(-)
13(8.8%) 69.2 53.8 15.4
Table 3 Multivariate analysis of the effect of
clinicopathological factors on overall survival in
laryngeal squamous cell carcinoma patients
Variables Overall survival
Odds ratio 95% CI P values
Cervical lymph node metastasis 3.708 1.952-7.041 < 0.001**
TGM2 2. 899 1.669-5.036 < 0.001**
BNIP3 0.324 0.188-0.559 < 0.001**
Primary Site 1.460 0.934-2.283 0.097
T Stage 1.485 0.871-2.534 0.147
*P < 0.05, **P < 0.01
Table 2 The relationship of clinicopathological variables
and immunohistochemical features with overall survival
(OS) in laryngeal squamous cell carcinoma patients
(Continued)
TGM2 (+) & BNIP3
(+)
57(38.5%) 73.7 66.7 53.8
TGM2 (-) & BNIP3
(-)
29(19.6%) 72.4 65.5 46.3
a Log-rank test.
b Patients were divided into two groups according to the
median age.
c Smoking index is defined as the number of cigarettes used per
day × the total smoking time (years). *P < 0.05, **P < 0.01
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and polymerization, or by destabilizing the association
of the p65/p50 (NF-B) complex with IB [27]. Aber-
rant activation of NF-B complexes can contribute to
tumorigenesis by regulating expression of genes which
promote cancer cell growth and survival. Constitutive
expression of NF-B has also been implicated in tumor
drug resistance. Recent experimental studies by Dae-
Seok Kim et al. demonstrated that inhibition of TGase 2
using siRNA, cystamine, glucosamine or R2 peptides
promotes cell death in drug-resistant cancer cells via
NF-B inactivation [29]; However, Barnes et al. [30]
suggested that reduced TGM2 activity is associated with
tumor growth and metastasis, while Fesus et al. reported
that increased activity of TGM2 in cells undergoing
apoptosis indicates a pro-apoptotic function [31]. Col-
lectively, these studies indicate that the role of TGM2
may depend on the type of cancer, the cell type and
cancer stage; and this study demonstrates that high
positive expression of TGM2 is associated with poorer
overall survival in laryngeal SCC patients receiving sur-
gery and postoperative radiotherapy.
Little is known about how TGM2 expression may
affect the treatment efficacy of radiotherapy. Yuan et al.
reported that the small molecule TGM2 inhibitor
KCC009, which inhibits the ability of TGM2 to bind
fibronectin and prevents the disposition of linear fibro-
nectin strands in the ECM, promotes apoptosis and
enhances radiosensitivity in cultured IOMM-Lee menin-
gioma cells and meningioma tumor explants [32]. Mian
et al. discovered that overexpression of TGM2 or a
cross-linking defective TGM2 mutant (C277S) in malig-
nant hamster fibrosarcoma cells (MetB) lead to delayed
S-phase to G2/M progression [33]. As the G2/M-phase
is the most sensitive phase to radiation, this observation
may explain the association between overexpression of
TGM2 and adverse outcome in patients receiving radio-
therapy. Though this evidence strongly suggests a role
for TGM2 in cancer, the exact molecular mechanism
which by high levels of TGM2 expression lead to an
adverse prognosis in laryngeal SCC is not know and
requires further research.
BNIP3 is strongly upregulated in response to hypoxia.
Generally, overexpression of BNIP3 induces necrotic-
like cell death, autophagy or apoptotic cell death. How-
ever, it has been suggested that the ability of BNIP3 to
induce cell death is blocked in cancer cells [34]. BNIP3
is downregulated in pancreatic ductal adenocarcinoma
and correlates with reduced patient survival [5,6]. BNIP3
is also downregulated in oxaliplatin-resistant colon can-
cer cells [7] and knockdown of BNIP3 using siRNA or
S100A4 results in resistance to fluorouracil (5-FU) and/
or gemcitabine in pancreatic ductal adenocarcinoma
cells [6], indicating that BNIP3 is an important regulator
during drug-induced cell death in cancer cells.
This study indicates that reduced expression of BNIP3
is associated with poorer overall survival in laryngeal
SCC patients receiving PRT. The ability of BNIP3 to
affect the efficacy of radiotherapy is poorly character-
ized. Kennedy et al. observed that overexpression of the
apoptosis-related gene BNIP3 could affect the sensitivity
of CRC cells to combined paclitaxel, radiation, and 5-FU
therapy [35], and the molecular mechanism by which
BNIP3 expression affects the prognosis of patients with
laryngeal SCC requires further study.
In this study we observed that BNIP3 expression was
correlated with TGM2 expression in laryngeal SCC (P =
0.012). TGM2 activates NF-B, via crosslinking and
polymerization or destabilizing the association of the
p65/p50 (NF-B) complex with IB [27]. Therefore, we
hypothesize that increased expression of TGM2 leads to
down-regulation of BNIP3 because BNIP3 expression
can be repressed through the transcription factor
nuclear factor kappa B (NF-B) binding to the bnip3
promoter [36].
The results of this study should be interpreted with
caution as this is a retrospective study of a relatively
small number of samples. Use of alternative methodolo-
gies such as microdissection and in-situ hybridization
and/or RT-PCR are required to confirm these results at
the RNA level.
Conclusions
The results of this study indicate that the expression
levels of BNIP3 and TGM2 are novel predictive factors
of survival in laryngeal SCC patients treated with sur-
gery and postoperative radiotherapy, and further study
is required to determine the molecular mechanisms by
which BNIP3 and TGM2 influence the prognosis of
these patients. Additionally, the mechanism regulating
the correlation between TGM2 and BNIP3 expression in
laryngeal SCC requires further investigation.
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